September 28, 2024Nutrients23 citationsOpen Access
Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study
Key points are not available for this paper at this time.
Abstract
The combination of elexacaftor-tezacaftor-ivacaftor modulators (ETI) has improved clinical outcomes for people with cystic fibrosis (pwCF).
Perguntar à IA
Like
Bookmark
Share
View Full Paper
Perguntar à IA
Like
Bookmark
Share
View Full Paper
Impact of Elexacaftor–Tezacaftor–Ivacaftor Therapy on Body Composition, Dietary Intake, Biomarkers, and Quality of Life in People with Cystic Fibrosis: A Prospective Observational Study | Synapse